Argitalpenak (135) Ikertzaileren baten partaidetza izan duten argitalpenak

2024

  1. Allelic variants of the estrogen receptor genes and frailty phenotype in postmenopausal women

    Climacteric, Vol. 27, Núm. 3, pp. 314-320

  2. Association between anxiety and frailty in postmenopausal women

    Gynecological Endocrinology, Vol. 40, Núm. 1

  3. Effect of fezolinetant on sleep disturbance and impairment during treatment of vasomotor symptoms due to menopause

    Maturitas

  4. Fezolinetant impact on health-related quality of life for vasomotor symptoms due to the menopause: Pooled data from SKYLIGHT 1 and SKYLIGHT 2 randomised controlled trials

    BJOG: An International Journal of Obstetrics and Gynaecology

  5. Physical activity to reduce the burden of frailty after menopause: effectiveness and adherence rate of a resource saving exercise plan

    Menopause, Vol. 31, Núm. 7, pp. 634-640

2023

  1. Analysis of the impact, patterns of care, and perspectives of patients and physicians about moderate-to-severe menopausal vasomotor symptoms in Spain

    Clinica e Investigacion en Ginecologia y Obstetricia, Vol. 50, Núm. 4

  2. Association of the rs17782313, rs17773430 and rs34114122 Polymorphisms of/near MC4R Gene with Obesity-Related Biomarkers in a Spanish Pediatric Cohort

    Children, Vol. 10, Núm. 7

  3. Both reduced ovarian reserve and severe semen alterations are overrepresented in couples seeking assisted reproductive technology treatment for the first time: a cross-sectional study

    Reproductive Health, Vol. 20, Núm. 1

  4. Breaking down barriers for prescribing and using hormone therapy for the treatment of menopausal symptoms: an experts’ perspective

    Expert Review of Clinical Pharmacology, Vol. 16, Núm. 6, pp. 507-517

  5. Corrigendum to “Evaluation of the impact, treatment patterns, and patient and physician perceptions of vasomotor symptoms associated with menopause in Europe and the United States” [Maturitas 164 (October 2022) 38–45] (Maturitas (2022) 164 (38–45), (S0378512222001360), (10.1016/j.maturitas.2022.06.008))

    Maturitas

  6. Erratum to: Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA (The journal of nutrition, health & aging, (2017), 21, 1, (92-104), 10.1007/s12603-016-0803-1)

    Journal of Nutrition, Health and Aging

  7. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study

    The Lancet, Vol. 401, Núm. 10382, pp. 1091-1102

  8. Genetic variants of the vitamin D receptor are related to dynapenia in postmenopausal women

    Maturitas, Vol. 171, pp. 40-44

  9. Long-term effect of chemotherapy after ovarian decortication on the ovarian function in women surviving cancer

    Journal of Assisted Reproduction and Genetics, Vol. 40, Núm. 12, pp. 2827-2834

  10. Mediterranean diet for cancer prevention and survivorship

    Maturitas, Vol. 178

  11. Prophylactic mastectomy and bilateral salpingo-oophorectomy in patients with breast cancer: a systematic review of postsurgical sexual function and menopausal hormone therapy symptom mitigation

    Sexual medicine reviews, Vol. 12, Núm. 1, pp. 3-13

  12. Rodent Animal Models of Endometriosis-Associated Pain: Unmet Needs and Resources Available for Improving Translational Research in Endometriosis

    International Journal of Molecular Sciences, Vol. 24, Núm. 3

  13. Safety of Fezolinetant for Vasomotor Symptoms Associated with Menopause: A Randomized Controlled Trial

    Obstetrics and Gynecology, Vol. 141, Núm. 4, pp. 737-747

  14. Sequential management of postmenopausal health and osteoporosis: An update

    Maturitas, Vol. 177

  15. The covid-19 pandemic and the usability of telehealth in a midlife women's health integrated care program

    Maturitas, Vol. 168, pp. 7-12